Drug-resistant epilepsy and topiramate: plasma concentration and frequency of epileptic seizures.

Topiramate (TPM) is a second-generation antiepileptic drug (AED), acting on drug-resistant epilepsy. The aim of the study was to evaluate the influence of the dose, use of other AEDs on TPM plasma concentration (C-p), and frequency of epileptic seizures. A cross-sectional analytical study was developed with patients aged 18-60years, for diagnosis of drug-resistant epilepsy, using TPM in monotherapy or associated with other AEDs. The following variables were analyzed: age, frequency of epileptic seizures, pharmacotherapeutic regimen with its respective doses, adherence to medication treatment, and adverse events score. Thirty-seven patients were included, 83.8% of the patients presented C-p below the therapeutic range. Multiple linear regression estimated that the increase of 1.0 mg/kg/d promoted an increase of 0.68 mu g/mL in TPMCp, while the use of inducers predicted a reduction of 2.97 mu g/mL (P < .001). Multiple Poisson regression predicts that an increase of 1.0 mu g/mL in TPMCp decreased the patient's chance of presenting seizures, and patients using AED inducers were about ten times more likely to present seizures than those who do not use (P < .001). In addition, for patients using AED inducers with C-p below the therapeutic range, the mean number of seizures per month was greater than those with C-p within the therapeutic range. The prescribed dose and the use of AED inducers influence C-p of TPM, likewise the low C-p of first-line AEDs and of the adjuvant in the treatment, TPM, as well as low TPM dose seem to affect the control of epileptic seizures.